key: cord-0014388-4i9xw404
authors: Vallejo-Gracia, Albert; Chen, Irene P.; Perrone, Rosalba; Besnard, Emilie; Boehm, Daniela; Battivelli, Emilie; Tezil, Tugsan; Krey, Karsten; Raymond, Kyle A.; Hull, Philip A.; Walter, Marius; Habrylo, Ireneusz; Cruz, Andrew; Deeks, Steven; Pillai, Satish; Verdin, Eric; Ott, Melanie
title: FOXO1 promotes HIV Latency by suppressing ER stress in T cells
date: 2020-06-15
journal: Nat Microbiol
DOI: 10.1038/s41564-020-0742-9
sha: cdc19826ae8c0bb6ca6ce9fa507990e3ad79b3da
doc_id: 14388
cord_uid: 4i9xw404

Quiescence is a hallmark of CD4(+) T cells latently infected with HIV-1. While reversing this quiescence is an effective approach to reactivate latent HIV from T cells in culture, it can cause deleterious cytokine dysregulation in patients. As a key regulator of T-cell quiescence, FOXO1 promotes latency and suppresses productive HIV infection. We report that in resting T cells, FOXO1 inhibition impaired autophagy and induced ER stress, thereby activating two associated transcription factors: activating transcription factor 4 (ATF4) and nuclear factor of activated T cells (NFAT). Both factors associate with HIV chromatin and were for HIV reactivation. Indeed, inhibition of PKR-like endoplasmic reticulum kinase (PERK), an ER stress sensor that can mediate the induction of ATF4, and calcineurin, a calcium-dependent regulator of NFAT, synergistically suppressed HIV reactivation induced by FOXO1 inhibition. Thus, our studies uncover a link between FOXO1, ER stress, and HIV infection that could be therapeutically exploited to selectively reverse T-cell quiescence and reduce the size of the latent viral reservoir.

uncover a link between FOXO1, ER stress, and HIV infection that could be therapeutically exploited to selectively reverse T-cell quiescence and reduce the size of the latent viral reservoir.

The major barrier to eradicating human immunodeficiency virus (HIV-1) from infected patients is the persistence of latently infection, primarily of memory CD4 + T cells. These cells are rare, long-lived, and generally quiescent. Although anti-retroviral therapy (ART) effectively suppresses HIV replication, therapy interruption results in reactivation of the latent reservoir, necessitating life-long treatment, and there is no cure 1, 2 . One strategy to eliminate latently infected cells is to activate virus production with latency reversing agents (LRAs) to trigger cell death through virus-induced cytolysis or immune clearance. Efficient viral reactivation requires a calibrated degree of activation that avoids inducing polyclonal T cell activation or a cytokine storm that would negate the potential benefit. Known LRAs include PKC agonists (e.g. Prostratin), epigenetic modulators (e.g. HDAC or bromodomain inhibitors), and modulators of the PI3K or mTOR signaling pathways [3] [4] [5] [6] . However, clinical trials of existing LRAs have not yet demonstrated successful reduction of the latent reservoir 7 . Thus, a better understanding of how HIV latency is established and maintained is needed to improve the design of interventions.

The Forkhead box O (FOXO) protein family comprises evolutionarily conserved transcription factors 8 . FOXO-mediated gene regulation is determined in part by localization; upon phosphorylation by upstream kinases, they exit the nucleus and remain inactive. FOXO isoforms influence multiple pathways, including cell cycle arrest, glucose metabolism, oxidative stress regulation, apoptosis, and the DNA damage response [9] [10] [11] . In the immune system, FOXO proteins regulate a set of genes involved in maintaining quiescence and cellfate differentiation in CD4 + and CD8 + T cells [12] [13] [14] . Furthermore, inhibition of FOXO1 in naïve and memory CD8 + T cells promotes a more effector-like and cytotoxic phenotype in the context of immune aging and chronic infection 15 .

In elite controller HIV patients, FOXO3a is downregulated in memory CD4 + T cells, promoting the persistence of these cells 16 . Furthermore, FOXO proteins negatively regulate HIV transcription through Tat-mediated repression 17 , and FOXO1 inhibition accelerates productive infection 18 . Because FOXO1 activity promotes and maintains the quiescent state of memory CD4 + T cells, in which HIV establishes latency, we hypothesized that FOXO1, directly or indirectly, induces HIV latency. Here, we identify a pathway that links HIV latency with FOXO1 activity via ER stress signaling, but without general T cell activation. Having shown that FOXO1 inhibition prevents latency establishment and successfully purges the virus from its latent reservoirs, we propose that the combination of early ART and FOXO1 inhibition may downsize the latent reservoir. In support of our findings, a recent study also showed the potential for FOXO1 inhibition to reactivate HIV latent proviruses 19 .

To test the potential of FOXO1 inhibition to affect HIV-1 latency, we used the secondgeneration dual-color reporter virus HIV GKO 20 and AS1842856 (Figure 1a) , a cell-permeable inhibitor of FOXO1 known to inhibit hepatic glucose production 21 . In this system, latently infected K562(Cas9) cells and the T cell-based cell line NH7 express the mKO2 fluorescent protein under the control of the EF1α promoter, while cells containing a productive and active virus express both mKO2 and GFP fluorophores, the latter controlled by the HIV-1 LTR. Upon treatment with increasing concentrations of AS1842856, the proportion of latently infected cells decreased, despite no significant changes in the total infection rate or viability (Figure 1a and Extended Data Figure 1a) . Concomitantly, the proportion of actively infected cells increased, as expected. The IC 50 of the inhibitor observed in our cell culture system was 74 ± 15 nM, near its in vitro IC 50 of 33 nM 21 . Thus, FOXO1 inhibition prevented HIV-1 latency establishment and increased the ratio between actively-and latently-infected cells.

We next sought to confirm the specificity of AS1842856 for FOXO1. To that end, we performed cellular thermal shift assays (CETSA) against the FOXO isoforms expressed in K562(Cas9) cells. CETSA evaluates biophysical binding under physiological conditions in living cells. Binding was considered 'positive' if there was a significant change in the thermal denaturation profile of the protein upon addition of AS1842856 (Extended Data Figure 1b ). We observed a 5. Figure  1e ). Because FOXO proteins control the cell cycle and promote a quiescence, each knockdown increased the proliferation rate (Extended Data Figure 1f ), in agreement with previous findings on human bladder cancer cells 22 and MCF-7 breast adenocarcinoma cells 23 . However, only FOXO1 downregulation increased productive infection and decreased latent infection (Figure 1d ), although the effect was modest. Furthermore, FOXO1 knockdown rendered infected cells more sensitive to AS1842856 treatment, shifting the IC 50 ( Figure 1e and Extended Data Figure 1g -i). Taken together, these data indicate that pharmacological or genetic inhibition of FOXO1, but not FOXO3 or FOXO4, decreases establishment of HIV-1 latency.

The J-Lat clonal cell lines are Jurkat cells that contain a stably integrated, latent HIV-1 (HXB) ∆ env provirus with a GFP reporter gene in place of the nef gene 24 . In this system, reactivation from established latency can be monitored through GFP mRNA and protein expression. After 48 and 72 hours of treatment, AS1842856 stimulated GFP mRNA expression in J-Lat 5A8 cells to a similar degree as TNFα, a known LRA in J-Lat cells, indicating that FOXO1 inhibition can also reverse established latency (Figure 2a ). No major effect on cell viability was observed (Figure 2b ). Maximal activation by TNFα was seen after 24 hours, while AS1842856-induced activation progressively increased only after this time point.

Treatment with AS1842856 also increased HIV-driven GFP protein expression, similar to mRNA expression, in a dose-dependent manner, as determined by flow cytometry (Figures  2c, d) . Because FOXO1 and FOXO4 antagonize transactivation of the HIV-1 promoter through the repression of the viral transactivator Tat 17 , we tested the ability of AS1842856 to reverse HIV latency in J-Lat cells with and without Tat. AS1842856 increased GFP expression in both J-Lat A2 cells, which do contain Tat, and in A72 cells, which do not 24 , indicating that the effect of FOXO1 inhibition on HIV reactivation is Tat-independent, although overall levels of reactivation are higher when Tat is present (Figure 2c ), in agreement with other reports 19 . No effect on cell viability was observed in either cell line ( Figure 2c ).

To rule out effects based on clonal variation or proviral integration sites, we compared AS1842856-induced HIV reactivation in four J-Lat clonal cell lines which harbor latent HIV-1 inserted at distinct genomic sites. After 72 hours of treatment, AS1842856 reactivated HIV in each cell line, as determined by percentage of GFP + cells ( Figure 2d ) and the median fluorescence intensity (Extended Data Figure 2a ). In all cell lines, viability was unaffected, and treatment with TNFα induced GFP expression as early as 24 hours after treatment, as expected ( Figure 2d) . Thus, the effect of AS1842856 is independent of the proviral integration site.

Given the different time courses of TNFα-and AS1842856-induced HIV reactivation, we speculated that these LRAs target different mechanisms of reactivation and might synergize.

To test this hypothesis, we co-treated multiple J-Lat lines with increasing concentrations of AS1842856 and TNFα (Extended Data Figure 2b , c). We used the Bliss independence model to assess dose combinations that result in greater than additive effects 25, 26 and observed such synergistic effects across different doses in all clones (Figure 2e , upper panels). There were no major changes in viability in co-treated cell lines (Figure 2e , bottom panels). These data show reversal of established latency by FOXO1 inhibition and indicate a molecular mechanism of activation distinct from TNFα.

To verify these results in primary T-cell models of HIV latency, we measured the capacity of FOXO1 inhibition to impair HIV latency establishment by infecting resting CD4 + T cells from anonymous blood donors with HIV GKO while treating the cells with increasing doses of AS1842856 for 72 hours. As previously observed in K562(Cas9) cells, inhibition of FOXO1 promoted productive infection and decreased latency (Figure 3a ). We also tested the ability of AS1842856 to reverse established HIV latency in primary cells by spin-infecting resting CD4 + T cells with a pseudotyped HIV reporter virus containing the firefly luciferase gene 27 . After 6 days in culture, cells reactivated luciferase expression in response to increasing concentrations of FOXO1 inhibitor (Figure 3b ) as well as in response to generalized T cell activation induced with a combination of phytohemagglutinin and interleukin-2 (PHA/IL-2) or with antibodies directed against the CD3 and CD28 receptors (Extended Data Figure 3a) . Notably, FOXO1 inhibition did not induce generalized T cell activation, as measured by expression of CD69 and CD25 activation markers on the cell surface (Extended Data Figure 3b ). Combining AS1842856 (100 nM) with a low dose of prostratin (250 nM), a natural PKC activator that induces partial T-cell activation 25, 28 , significantly increased the AS1842856 effect in primary T cells, mirroring the synergistic effect of TNFα in J-Lat cells. No change in primary T-cell viability was observed in response to FOXO1 inhibition (Figures 3a-c) .

We replicated these observations in CD4 + T cells, isolated from ten HIV-infected patients on antiretroviral therapy for at least 6 months and with undetectable viral loads (< 50 copies/ ml). Cells were treated ex vivo with two concentrations of AS1842856 (100 and 1,000 nM), prostratin (250 nM) or combinations thereof for 3 days, and HIV RNA induction was measured by digital droplet PCR (ddPCR). A two-fold induction was observed with AS1842856 treatment alone, which was significantly enhanced with prostratin cotreatment to similar levels as achieved by PMA/I treatment (Figure 3c) . These results confirm a role of FOXO1 in the establishment and maintenance of HIV latency in primary resting T cells.

To determine how FOXO1 inhibition changes the transcriptome of resting CD4 + T cells, we performed RNA sequencing (RNA-Seq) on primary CD4 + T cells treated with AS1842856 or DMSO for 12 hours. AS1842856 treatment resulted in up-regulation of 246 genes and down-regulation of 473 genes (q < 0.05) (Figure 4a ). Ingenuity Pathway Analysis of the upregulated genes revealed significant enrichment of genes involved in tRNA charging (e.g. GARS, MARS, VARS), T and B cell signaling and cytokine production (e.g. IL10, CSF2, SLAMF1), and dysregulation of the endoplasmic reticulum: ER stress pathway (ER stress) and Unfolded Protein Response (UPR) (e.g. CALR, ATF4, HSPA5). Down-regulated genes included those involved in granzyme A signaling (e.g. HIST1), cell junction signaling (e.g. IRS2, ATM), and autophagy (e.g. ATG13, ATG9A, CTSF, NBR1, RB1CC1, ULK1) ( Figure   4b ). Notably, the autophagy pathway is an established target of FOXO1 29, 30 . These results were largely aligned with a recently published microarray analysis in T cells treated with AS1842856 for 7 days 19 (Extended Data Figure 4a ).

We confirmed down-regulation of autophagy markers and up-regulation of ER stress markers, in AS1842856-treated healthy CD4 + T cells ( Figure 4c ) and in HIV-infected samples (Extended Data Figure 4b ) by real-time quantitative PCR (RT-qPCR). Furthermore, in CD4 + T cells FOXO1 inhibition increased the level of the spliced form of the X boxbinding protein 1 (XBP-1s), an important transcription factor in the ER stress response 31 , and the phosphorylation of its upstream activator, inositol-requiring enzyme 1α (IRE1α), whereas eif2α levels remained unchanged (Figure 4d ). FOXO1 inhibition also increased protein aggregation in the cytoplasm of CD4 + T cells (Figure 4e , f), especially in the ER (Figure 4e , Extended Data Figure 4c ), suggesting that protein accumulation and ER stress may be a result of decreased FOXO1-mediated autophagy.

Upstream regulator analysis identified ATF4 as the top modulator of AS1842856-induced genes ( Figure 5a ). ATF4 is a transcription factor specifically upregulated at the protein level as part of the UPR and the integrated stress response (ISR), which involves phosphorylation of the translation initiation factor eIF2α by stress-specific kinases [32] [33] [34] . Consistent with this data, FOXO1 inhibition increased expression of ATF4 protein levels in CD4 + T cells across multiple donors (Figure 5b ). Given that the ER is an important storage organelle for calcium 35 and that ER stress induces calcium release 36 , we performed calcium flux measurements in AS1842856-treated CD4 + T cells ( Figure 5c ) and K562(Cas9) and Jurkat cell lines (Extended Data Figure 5 ). Basal calcium levels were increased in response to AS1842856 treatment, whereas calcium ER flux levels increased modestly yet significantly after the addition of the Ca 2+ ionophore ionomycin in primary CD4 + T cells (Figure 5c ) as compared to Jurkat cells, consistent with previous results 19 .

Because previous research demonstrated that ATF4 binds the simian immunodeficiency virus (SIV) and HIV LTR 37 and activates the related human T-cell leukemia virus type 1 (HTLV-1) 38 , we performed chromatin immunoprecipitation (ChIP) experiments to test whether ATF4 binds the HIV LTR in response to FOXO1 inhibition. While low levels of ATF4 bound HIV LTR chromatin in untreated J-Lat cells, its recruitment was 3-fold enriched after AS1842856 treatment ( Figure 5d ). We also observed a marked increase in RNA polymerase II recruitment to the HIV promoter after FOXO1 inhibition, consistent with HIV transcription reactivation. Since we observed increased calcium release upon FOXO1 inhibition, we asked whether FOXO1 inhibition also altered HIV promoter occupancy of nuclear factor of activated T cells (NFAT), which drives HIV transcription activated through calcium mobilization after T-cell activation 39, 40 . NFAT was markedly enriched at the HIV LTR after FOXO1 inhibition ( Figure 5d ). In contrast, the RelA subunit of NF-κB, which regulates HIV transcription in response to T cell activation or TNFα exposure 41 , was not recruited to the HIV LTR after AS1842856 treatment but was significantly enriched after TNFα treatment, as expected ( Figure 5d ). Consistent with those results, NFAT can occupy the NF-κB binding sites in the HIV LTR 42 , indicating that FOXO1 in resting T cells suppresses a (non-canonical) transcriptional program that controls HIV transcription without NF-κB, but with ATF4 and NFAT. This result explains the synergy observed between AS1842856 and TNFα or prostratin, which activate HIV through NF-κB 28 .

To investigate the role of the integrated stress response (ISR) in HIV reactivation, we evaluated the effect of AS1842856 in combination with inhibitors of the eIF2α upstream kinases: double-stranded RNA-dependent protein kinase R (PKR), activated by viral infection; PKR-like endoplasmic reticulum kinase (PERK), activated in response to ER stress; and general control nonderepressible 2 (GCN2) kinase, activated by amino acid deficiencies [43] [44] [45] [46] [47] [48] . Treatment with two pharmacological inhibitors of PERK ( Figure 6a ), but not inhibitors of GCN2 or PKR (Extended Data Figure 6a ,b), reduced AS1842856-induced HIV reactivation, consistent with the model that FOXO1 inhibition activates ATF4 through ER stress-driven PERK activation. In contrast, TNFα-mediated HIV reactivation was not affected by PERK inhibition (Figure 6a ) but was diminished by GCN2 or PKR inhibitor treatment (Extended Data Figure 6a ,b), underscoring the distinct molecular mechanisms underlying latency reversal by the two activators. Similar results were observed in CD4 + T cells from three HIV-infected individuals ( Figure 6b ). Interestingly, inhibition of IRE1α, which represents a separate branch of the ER Stress pathway, did not affect HIV reactivation induced by FOXO1 inhibition (Extended Data Figure 6d ), although the compound successfully suppressed XBP-1s-dependent ER stress induction by thapsigargin (Extended Data Figure 6e ). Thus, while FOXO1 inhibition induces protein aggregates and ER stress, HIV latency reactivation appears exclusively dependent on the PERK-ATF4 branch of the UPR.

Because NFAT was also recruited to the HIV LTR after FOXO1 inhibition but is not regulated by PERK activation, we tested the effect of cyclosporin A (CsA), a potent inhibitor of calcium release and NFAT mobilization known to reduce HIV transcriptional activity 49 .

Increasing concentrations of CsA suppressed HIV reactivation induced by AS1842856, but not TNFα, supporting a specific role of NFAT in FOXO1 inhibitor-mediated latency reversal ( Figure 6c ). Treatment with the PERK inhibitor or CsA alone suppressed HIV reactivation by ~ 42.5 % (49 ± 22 % (PERKi); 36 ± 7 % (CsA)), whereas the combination almost completely blocked AS1842856-mediated viral reactivation (83 ± 4 %) (Figure 6d ), without affecting cell viability (Extended data Figure 6c , f). This result suggests that both ATF4 and NFAT are important for HIV reactivation in response to FOXO1 inhibition.

To validate the effect of ER stress on HIV reactivation, we treated J-Lat cells with known inducers of ER stress 50 : thapsigargin, tunicamycin, brefeldin A and fenretinide. All resulted in HIV-1 reactivation, with fenretinide exerting the most potent effect (Figure 6e ). Each of these agents induced dose-dependent cellular toxicity, as expected 51 (Extended Data Figure  6g ). To minimize toxicity caused by high concentrations of fenretinide, we combined a nontoxic dose of fenretinide (0.5 μM) with increasing amounts of ionomycin to mobilize additional Ca 2+ ions. Ionomycin alone was sufficient to induce HIV reactivation (Extended Data Figure 6h ), but the combination with fenretinide significantly increased the effect (~64fold over fenretinide alone), with minimal toxicity (Figure 6f and Extended Data Figure 6i ). These data support a model in which FOXO1 interferes with potentially low-level chronic ER stress in resting T cells, preventing activation of ATF4 and NFAT, thereby promoting HIV latency. In turn, inhibition of FOXO1 activity promotes protein accumulation in the ER leading to ER stress signaling and calcium release, which mobilizes ATF4 and NFAT and activates HIV-1 transcription ( Figure 6g ).

By uncovering a link between FOXO1 and ER stress, this work describes a mechanism through which HIV latency is established and maintained in quiescent CD4 + T cells. Our results are in agreement with work linking ER stress with CD4 + T cell activation 43, 52 , and show that FOXO activity protects quiescent cells from oxidative stress 53 . We further show that this effect does not involve NF-κB activity, but that FOXO1 activity controls ATF4 and NFAT mobilization. In other systems, ATF4 interacts with FOXO1 and regulates glucose metabolism in osteoblasts 54 , while FOXO activity suppresses calcineurin/NFAT activation by reducing oxidative stress in cardiac physiology 55, 56 .

Malfunction of the ER, such as excessive secretory activity, Ca 2+ depletion, or presence of misfolded proteins, has a pivotal role in establishment of latent viral infections. ER stress activates the UPR, which is necessary for replication of many viruses, such as herpes viruses 57 . Other viruses are known to hijack the UPR to promote expression of ATF4, including hepatitis C virus 58 , West Nile virus 59 , respiratory syncytial virus 60 , Japanese encephalitis virus 61 , human cytomegalovirus 62 , dengue virus (DENV) 63 , and infectious bronchitis virus (IBV) 64 . In the context of HIV, our work shows that ER stress promotes active HIV infection, with FOXO1 acting as a critical regulator of this process in resting T cells. These results are in agreement with previous findings that HIV-1 infection is associated with enhanced expression of the ER stress sensors PERK, ATF4, ATF6, and IRE-1 in PBMCs [65] [66] [67] , and that the viral protein Tat induces ER stress in astrocytes 68 .

While NFAT is not a "classical" ER stress-induced factor, it can be activated by ER stress 69 .

In addition, its close connection with intracellular calcium levels links it to the ER, where the majority of intracellular calcium is stored 35 . Prolonged ER stress is associated with calcium release, and the ER-resident chaperone binding immunoglobulin protein (BiP), a sensor of unfolded proteins, is itself calcium-regulated 70 . In the absence of ER stress, BiP is bound to monomeric PERK in the ER membrane. When BiP senses the accumulation of misfolded proteins, it dissociates from PERK, allowing the kinase to dimerize and transautophosphorylate 31 . Phosphorylated PERK promotes phosphorylation of eIF2α, which impairs translation of most mRNAs, with the exception of a few transcripts like ATF4 71 . We hypothesize that this cascade of events explains the late reactivation kinetics of FOXO1 inhibition.

Further experiments are required to better understand the molecular link between FOXO1, ER stress and proteostasis. We demonstrate that in quiescent T cells, FOXO1 inhibition down-regulates autophagy genes and leads to an increased protein accumulation. Other studies have linked FOXO activity to autophagy induction 29, 30, 72 , and the loss of dFOXO in Drosophila attenuates autophagy 73 . While our current data point to inhibition of autophagy, protein accumulation in the ER and a broad activation of ER stress responses as the cause of HIV reactivation in response to FOXO1 inhibition, we cannot exclude a direct effect of FOXO1 on the PERK-ATF4 pathway. PERK is known to phosphorylate FOXO1 to enhance insulin responsiveness 74 but no reciprocal effect of FOXO1 on PERK activity has yet been reported. Furthermore, it is unclear whether T cell physiology impacts the phosphorylation state of FOXO1 upon AS1842856 inhibition 21, 75 .

Nevertheless, the discovery of this mechanism opens the door to promising therapeutic options, especially considering the synergistic effects of FOXO1 inhibition in combination with other LRAs and the latency reversing effect of ER stress-inducing agents such as fenretinide, currently in early clinical trials for cancer 76 . Furthermore, the cytolytic activity of CD8 + T cells, key contributors to a successful "shock and kill" strategy, is strengthened by treatment with the FOXO1 inhibitor 15 , in contrast to HDAC inhibitors, which suppress CD8 + T cell activity 77 . A combination of FOXO1 inhibitors with early ART seems especially promising, given the negative effect on latency establishment, potentially prolonging the time window for intervention to prevent maximal reservoir establishment.

J-Lat cell lines (clones A2, A72, 6.3, 11.1 14.8 and 5A8) were obtained from the Verdin and Greene Laboratories at Gladstone Institutes, which generated these lines from Jurkat cells 24 

Cells were treated with the following compounds: 

Cells were seeded in drug-supplemented media in triplicates onto 96-well plates with a target cell density of 0.125-0.25-0.5 × 10 6 cells/mL, and then incubated at 37 °C for 72-48-24 hours, respectively. In preparation for flow cytometry, cells were washed in V-shaped 96-well plates (500 x g, 5 min, 4 °C), and stained with Fixable Viability Dye eFluor 780 (65-0865-14; ThermoFisher Scientific). For T cell activation analysis, CD69 and CD25 expression was measured by flow cytometry gating on CD3 + CD4 + T cells using FITClabeled antibodies for CD3 (11-0048-42, eBioscience), APC-conjugated CD25 antibodies (17-0259-42, eBioscience), PerCP-labeled antibodies for CD4 (300528, Biolegend), and CD69-V450 (560740, BD Horizon). Staining was performed for 30 min on ice in FACS buffer (PBS, 2% FBS) before analysis. 5A8 J-Lat cells were measured on a BD FACSCalibur system (BD Biosciences) in an uncompensated setting. Infected or uninfected K562(Cas9) and CD4+ T cell data was collected using the BD LSRII flow cytometer (BD Biosciences). Data were analyzed using FlowJo V10.1 software (Tree Star).

Cell viability (% survival) was measured by flow cytometry gating on forward and side scatter analysis and using Fixable Viability Dye eFluor 780 (65-0865-14; ThermoFisher Scientific). Trypan blue dye exclusion was used to evaluate the cell viability in the CETSA assays in K562(Cas9) cells and in the reactivation studies in HIV+ donors. A 10 μL cell aliquot from each sample was briefly mixed with an equal volume of 0.4% (w/v) trypan blue dye solution (Gibco, NY, USA) and counted. Cells with the ability to exclude trypan blue were considered viable.

For CETSA, K562(Cas9) cell were freshly seeded one day before the experiment. On the day of the experiment, equal numbers of cells were counted by Moxi Mini automated cell counter (Orflo) and 0.6×10^6 cells per data point were seeded in T-25 cell culture flasks (VWR, PA, USA) in appropriate volume of culture medium. Cells were exposed to 100 nM AS1842856 or equal DMSO volume for 3 hours in an incubator with 5% CO2 and 37°C. Following the incubation, cells were harvested, washed with PBS and diluted in PBS supplemented with EDTA-free complete protease inhibitor cocktail (ROCHE). Then, the cells were divided into 100 μl aliquots and heated individually at different temperatures for 3 minutes (Thermal cycler, BIO-RAD) followed by cooling for 2 minutes at room temperature. Cell suspensions were freeze-thawed three times with liquid nitrogen. The soluble fraction was separated from the cell debris by centrifugation at 20000 g for 20 minutes at 4°C. The supernatants were transferred to new microcentrifuge tubes and analyzed by SDS-PAGE followed by immunoblotting analysis. CETSA experiments were performed as triplicates on different days. Immunoblotting results were subjected to densitometric analysis (Image J) and melting temperatures of FOXO1, FOXO3 and FOXO4 were determined by Prism 7 (GraphPad) using nonlinear least-squares regression fit to Y = 100/ (1 + 10 ^ (Log IC 50 -X) *H), where H = Hill slope (variable). The viability of the cells was assessed in triplicate by trypan blue exclusion.

Individual sgRNAs from human v2 library 83 were cloned into lentiviral vectors expressing either a Puromycin resistance cassette (60955, Addgene) or into a modified vector expressing a Blasticidin resistance cassette (Gift from Nevan Krogan, UCSF). Lentiviruses were prepared in HEK293T. For single knockdowns, K562(Cas9) cell lines expressing dCas9-BFP-KRAB were transduced with a single construct and pooled selected with either Puromycin (1 μg/mL, Sigma-Aldrich) or Blasticidin (10 μg/mL, Sigma-Aldrich). See Table  1 .

Primary naïve CD4+ T cells were isolated from PBMCs through negative selection (19555, STEMCELL Technologies) and treated with AS1842856 for 72 hours. Cells were collected after treatment and plated onto poly-l-lysine (P4707, Sigma-Aldrich) coated, 22-by 22-mm no. 1.5 coverslips. Cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and blocked in 3% bovine serum albumin. Cells were then immunostained with the indicated antibodies: Anti-GRP78-Alexa Fluor 647 (PA1-014A-A647, Invitrogen), Proteostat Aggregate Stain (enz-51035-K100, Enzo Life Sciences), and Hoescht 33258 (H3569, Invitrogen). Coverslips were mounted onto glass slides using ProLong Gold Antifade Mountant (P36934, Invitrogen) and analyzed by confocal microscopy (Zeiss LSM 880). High-resolution images were acquired on the Zeiss LSM 880 with Airyscan using a 63×/1.4 M27 oil immersion objective. The resulting Z-stack was reconstructed and rendered in 3D using Imaris software (Bitplane). Images were formatted for publication with ImageJ. Protein aggregate foci were reconstructed via the Imaris spot detection function, which provided an analysis of total number of aggregates within a cell. The Imaris spot detection function identifies foci based on fluorescence intensity. The Imaris colocalization function was used to determine overlap of fluorescence. Thresholding for background fluorescence was determined by the Imaris automatic thresholding tool, which utilizes the Costes approach. The thresholded Mander's correlation coefficient (MCC) measures the fraction of voxels with fluorescence positive for one channel that also contains fluorescence from another channel.

Cells were lysed in radioimmunoprecipitation assay buffer ( 

Total RNA from samples was extracted using the Direct-zol RNA kit (R2060; Zymogen). cDNA was generated using 500 ng for CD4 + T cells or 1,000 ng of total RNA for J-Lats with Superscript III reverse transcription (18080-044; ThermoFisher) and oligo(dT) [12] [13] [14] [15] [16] [17] [18] (18418-012; ThermoFisher). Quantitative RT-PCR was done using Maxima SYBR Green qPCR Master Mix (Thermo Scientific) on SDS 2.4 software (Applied Biosystems) in a total volume of 12 μL. The SYBR green qPCR reactions contained 5 µl of 2× Maxima SYBR green/Rox qPCR Master Mix (K0221; ThermoFisher), 5 µl of diluted cDNA, and 1 nmol of both forward and reverse primers. The reactions were run as follows: 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 5 s and 62°C for 30 s. See Table S2 for a qRT-PCR primer list. Primer efficiencies were around 100%. Dissociation curve analysis after the end of the PCR confirmed the presence of a single and specific product. All qPCRs were independently repeated at least three times, averaged and compared using standard deviation (±SD).

This study sampled HIV-infected participants from the Zuckerberg San Francisco General Hospital clinic SCOPE cohorts. These individuals met the criteria of having had started ART during chronic infection and being under suppressive ART, with undetectable plasma HIV-1 RNA levels (<50 copies/mL) for a minimum of one year. The UCSF Committee on Human Research approved this study (IRB #10-01330), and the participants gave informed, written consent before enrollment. Peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood (100 mL) using Lymphocyte Separation Medium (25- 

For reactivation of latent HIV-1 provirus, cells were counted and collected as pellets by centrifugation at 1500 rpm for 10 min. Cells were then plated in 96-well U-bottom plates at 

To analyze drug combinatorial effects, we used the Bliss independence model from the SynergyFinder web application (https://synergyfinder.fimm.fi) 84 . The Bliss score (∆f axy ) is the difference between the calculated reactivation value if the two drugs act independently and the observed combined reactivation values. Synergy is defined as ∆f axy > 0, while ∆f axy < 0 indicates antagonism. Positive Bliss scores represent dose combinations which have greater than additive effect 26 .

RNA was prepared from CD4 + T cells using the QIAgen RNeasy Plus Kit. The Gladstone Institutes Genomics Core carried out the downstream processing of the RNA samples. Strand-specific cDNA libraries were prepared using the Nugen Ovation kit (Nugen) and the libraries were deep sequenced on NextSeq 500 using single-end 75 bp sequencing. RNA-seq analysis was done using the Illumina RNAexpress application v 1.1.0. Briefly, alignment of RNA-Seq reads was performed with the STAR aligner and, after alignment of aligned reads to genes, differential gene expression was analyzed with DESeq2. Pathway analysis was carried out using Ingenuity Pathway Analysis (QIAGEN) and Gene Ontology AmiGO Term Enrichment tool (Biological Processes and Cellular Components). For the Ingenuity analysis, the entire dataset was uploaded, and a two-direction analysis carried using filters to restrict the analysis to differentially expressed genes as above. Refer to the manufacturer's website (http://www.ingenuity.com) for further details. For Gene Ontology, individual lists of genes were uploaded and analyzed separately. Venn diagrams were generated using the online tool: http://genevenn.sourceforge.net/.

For calcium flux measurement, cells were seeded in complete RPMI medium in presence or absence of AS1842856 (100 nM) at a density of 2.5 × 10 5 cells/mL, and then incubated at 37 °C for 72 hours. In preparation for flow cytometry, equal numbers of cells were washed and incubated with the membrane-permeable calcium sensor dye eFluor™ 514 (65-0859, eBioscience) in PBS for 15 min at room temperature. Changes in calcium intracellular free concentration were measured over 200 sec by flow cytometric analysis on a BD LSRII flow cytometer (BD Biosciences). Ionomycin (1μg/ml, Thermo Fisher Scientific) was added after 30 sec. related fluorescence was measured on a BD FACSCalibur system (BD Biosciences) in an uncompensated setting). Data were analyzed using FlowJo V10.1 software (Tree Star).

J-Lat A2, A72 and 5A8 cells were treated with TNFα (10 ng/ml) or AS1852856 (1,000 nM) for 72 hours. Cells were fixed with 1% formaldehyde (v/v) in fixation buffer (1 mM EDTA, 0.5 mM EGTA, 50 mM HEPES, pH 8.0, 100 mM NaCl), and fixation was stopped after 30 min by addition of glycine to 125 mM. The cell membrane was lysed for 15 min on ice (5 mM Pipes, pH 8.0, 85 mM KCl, 0.5% NP40, protease inhibitors). After washing with nuclear swell buffer (25 mM HEPES, pH 7.5, 4 mM KCl, 1 Mm DTT, 0.5% NP-40, 0.5 mM PMSF) and micrococcal nuclease (MNase) digestion buffer (20 mM Tris pH 7.5, 2.5 mM CaCl 2 , 5 mM NaCl, 1 mM DTT, 0.5 % NP-40), the pellet was resuspended in MNase buffer (15 mM 

Two groups were compared using a two-tailed Student's t-test. Multiple comparisons to a control were calculated using two-way ANOVA, followed by Dunnett's test. Data are presented as mean ± SD for independent biological replicates. Statistical significance is indicated in all figures by p-values. 

Extended

Refer to Web version on PubMed Central for supplementary material. a, Volcano plot from the RNA-Seq data comparing CD4 + T cells treated with AS1842856 (1,000 nM) versus DMSO control for 12 hours. Up-regulated (blue) or down-regulated (red) genes are q-value < 0.05 and log 2 fold change ≥ 1 or ≤ −1, respectively. b, IPA pathway analysis of the most dysregulated canonical pathways for the up-and down-regulated genes. c, Confirmation of up-or down-regulated expression after 6 and 48 hours treatment of specific genes from altered pathways by RT-qPCR, normalized to RPL13A mRNA. Data represent mean ± SD of n=3 individual donors. d, Representative blots of protein expression of the ER stress markers XBP-1s, phosphorylated IRE1α and total IRE1α and total eIF2α (control). Representative experiment of n=3 independent experiments. e, Representative confocal microscopy images of primary CD4+ T cells isolated from PBMCs. Cells were treated with AS1842856 (500 nM) for 72 hours and processed for immunostaining after treatment with Proteostat (protein aggregates, red), GRP78 (endoplasmic reticulum, green), and Hoechst (nuclei, blue). The scale bars represent 1μm. Data are representative of n=3 independent experiments. f, The number of protein aggregates per cell. Data are represented as box plots: Control (min: 0, Q1: 5, center: 7, Q3: 9 max: 14), AS1842856 (min: 3, Q1: 9, center: 10, Q3: 13, max: 22). The P value was calculated by a linear mixed model by residual maximum likelihood. p-value < 2 -16 . n = 135 cells per condition. specific for HIV-1 LTR Nuc0 or Nuc1. Chromatin was prepared from J-Lat A2 and 5A8 cells, in which the LTR was stimulated by 1,000 nM AS1842856 treatment, 10 ng/mL TNFα or which were left untreated/DMSO. Representative experiment of n=3 independent biological experiments. Data are represented as mean ± SD of n=3 independent technical replicates.

µM) for 24, 48 and 72 hours and HIV-GFP reactivation was analyzed by FACS. Data shown are mean ± SD of n≥3 independent experiments. f, J-Lat cell line A58 was treated with 0.5 µM Fenretinide and increasing concentrations of Ionomycin. HIV-GFP reactivation and cell viability were analyzed by FACS. Data are mean ± SD of n=3 independent experiments. g, Model: FOXO1 inhibition impairs autophagy, thus promoting protein accumulation and leading to ER Stress. Thus, ATF4 activation through PERK and NFAT via cytosolic calcium release will promote HIV transcription and will prevent HIV latency.

present and future: 30 years of HIV research

Soriano-Sarabia N & Margolis DM Eradicating HIV-1 infection: seeking to clear a persistent pathogen

Greene WC An Integrated Overview of HIV-1 Latency

The mTOR Complex Controls HIV Latency

The Road to an HIV Cure

Planelles V Novel Latency Reversal Agents for HIV-1 Cure

Lewin SR Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?

Goldrath AW & Stone EL FOXO transcription factors throughout T cell biology

Brunet A Characterization of the direct targets of FOXO transcription factors throughout evolution

Arden KC FoxOs at the crossroads of cellular metabolism, differentiation, and transformation

Maintenance of CD4 T cell fitness through regulation of Foxo1

Repressive Complex 2-Mediated Chromatin Repression Guides Effector CD8 + T Cell Terminal Differentiation and Loss of Multipotency

Continuous activity of Foxo1 is required to prevent anergy and maintain the memory state of CD8+ T cells

Metabolic reprogramming of human CD8+ memory T cells through loss of SIRT1

Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection

Mechti N FoxO4 negatively controls Tat-mediated HIV-1 transcription through the post-transcriptional suppression of Tat encoding mRNA

Suppression of Foxo1 activity and down-modulation of CD62L (L-selectin) in HIV-1 infected resting CD4 T cells

FOXO1 transcription factor plays a key role in T cell -HIV-1 interaction

Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4 + T cells

Discovery of Novel Forkhead Box O1 Inhibitors for Treating Type 2 Diabetes: Improvement of Fasting Glycemia in Diabetic db/db Mice

Foxo3a Suppression of Urothelial Cancer Invasiveness through Twist1, Y-Box-Binding Protein 1, and E-Cadherin Regulation

Kutuk O & Basaga H IKK-β mediates chemoresistance by sequestering FOXO3

A critical factor for cell survival and death

HIV reproducibly establishes a latent infection after acute infection of T cells in vitro

Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations

A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs

Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: Implications for treatment of latent infection

Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity

Brunnet A FOXO transcription factors: key regulators of cellular quality control

Signal integration in the endoplasmic reticulum unfolded protein response

The integrated stress response

ATF4-dependent transcription mediates signaling of amino acid limitation

Keeping the eIF2 alpha kinase Gcn2 in check

& Hetz C Calcium signaling at the endoplasmic reticulum: fine-tuning stress responses

Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis

HIV Exploits Antiviral Host Innate GCN2-ATF4 Signaling for Establishing Viral Replication Early in Infection Downloaded from

Functional interaction of the HTLV-1 transactivator Tax with activating transcription factor-4 (ATF4)

Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A

Identification of calcineurin as a key signalling enzyme in T lymphocyte activation

Activation of NF-κB

Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells

Roles of Endoplasmic Reticulum Stress in Immune Responses

Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation

Regulated Translation Initiation Controls Stress-Induced Gene Expression in Mammalian Cells

Small molecule inhibitors of the RNA-dependent protein kinase

Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development

5-d]pyrimidine Derivatives as Inhibitors of GCN2

NFAT1 Enhances HIV-1 Gene Expression in Primary Human CD4 T Cells

Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57

Lotan R Mechanisms of fenretinide-induced apoptosis

Modulation of Endoplasmic Reticulum Stress Controls CD4+ T-cell Activation and Antitumor Function

Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress

FoxO1 Protein Cooperates with ATF4 Protein in Osteoblasts to Control Glucose Homeostasis

Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice

Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling

Hu CCA & Lieberman PM Deregulation of KSHV latency conformation by ER-stress and caspase-dependent RAD21-cleavage

Hepatitis C virus envelope proteins regulate CHOP via induction of the Unfolded Protein Response

West Nile Virus Infection Activates the Unfolded Protein Response, Leading to CHOP Induction and Apoptosis

Endoplasmic Reticulum-Specifc Stress-Activated Caspase (Caspase-12) is Implicated in the Apoptosis of A549 Epithelial Cells by Respiratory Syncytial Virus

Encephalitis Virus Infection Initiates Endoplasmic Reticulum Stress and an Unfolded Protein Response

Alwine JC Human Cytomegalovirus Infection Activates and Regulates the Unfolded Protein Response

Vasudevan SG & Jans DA Novel dengue virus inhibitor 4-HPR activates ATF4 independent of protein kinase R e like Endoplasmic Reticulum Kinase and elevates levels of eIF2 a phosphorylation in virus infected cells

Upregulation of CHOP / GADD153 during Coronavirus Infectious Bronchitis Virus Infection Modulates Apoptosis by Restricting Activation of the Extracellular Signal-Regulated Kinase Pathway

HIV infection and antiretroviral therapy lead to unfolded protein response activation Retroviruses

Activating transcription factor 4 (ATF4) promotes HIV type 1 activation

Understanding of the functional role(s) of the Activating Transcription Factor 4(ATF4) in HIV regulation and production

He JJ HIV-1 tat induces unfolded protein response and endoplasmic reticulum stress in astrocytes and causes neurotoxicity through glial fibrillary acidic protein (GFAP) activation and aggregation

Altered activity patterns of transcription factors induced by endoplasmic reticulum stress

Major Chaperone Protein of the Endoplasmic Reticulum Lumen, Plays a Direct and Important Role in the Storage of the Rapidly Exchanging Pool of Ca2+

Wek RC Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells

FoxO3 Controls Autophagy in Skeletal Muscle In Vivo

Gene expression profiling identifies FKBP39 as an inhibitor of autophagy in larval Drosophila fat body

ER stress potentiates insulin resistance through PERK-mediated FOXO phosphorylation

Targeting FoxO1 with AS1842856 suppresses adipogenesis

C. go. ClinicalTrials.gov [Internet] Identifier: NCT02495415, Primary ID: FEN T-14 , Secondary ID: NCI-2015-01195, Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas Available

Villarroel VA & Katz SI Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation

Ruelas D & Greene WC Calcium/calcineurin synergizes with prostratin to promote NF-κB dependent activation of latent HIV

Greene WC Efficient delivery of lentiviral vectors into resting human CD4 T cells

Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24Gag

A Tool to Assess HIV-1 Latency Reversal Agents in Human Primary CD4+ T Cells

Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation

A web application for analyzing drug combination dose-response matrix data

We thank all members of the Ott, Verdin and Pillai laboratories for helpful discussions, reagents and expertise. We thank Dante Lacuadra and Austin Patel for assistance, Marielle Cavrois, Nandhini Raman, and the Gladstone Flow Cytometry Core for assistance with FACS, Natasha Carli, Jim McGuire and the Gladstone Genomics Core for assistance with RNA-Seq, John Carroll for graphics, Kathryn Claiborn and Brett Mensh for editorial assistance, and Veronica Fonseca and Lauren Weiser for administrative assistance. This work was supported by NIH/NIAID R01939 and NIH/NIAID R01985 to M.O., NIH/NIDA R01DA041742 and NIH/NIAID R01AI117864 to E.V., NIH/ NIGMS R01GM117901 to S.K.P., and NIH P30 AI027763 to Flow Cytometry Core. Research was also supported as part of the amfAR Institute for HIV Cure Research, with funding from amfAR grant number 109301. D.B. was also funded by the Gilead HIV Cure Mentored Scientist Award from the amfAR Institute for HIV Cure Research at the UCSF AIDS Research Institute (ARI).

 Figure 6 . Induction of ER stress promotes HIV reactivation. a, J-Lat cell line 5A8 were treated with increasing concentrations of PERKi (GSK2656157 / PERK inhibitor II) (top panels) or the highly specific PERK inhibitor (AMG PERK 44) (lower panels) and co-treated with 1,000 nM AS1842856 (72 hours) or 10 ng/mL TNFα (24 hours). HIV-GFP reactivation was analyzed by FACS and normalized to the control. Data shown are mean ± SD of n=3 independent experiments. b, Effect of 50 ng/ml PMA + 1 μM Ionomycin (PMA/I), AS1842856 (1,000 nM) and AS1842856 (1,000 nM) with 1 μM PERKi (GSK2656157 / PERK inhibitor II) on HIV-1 mRNA expression in CD4 + T cells of n=3 HIV-infected patients on antiretroviral-therapy with undetectable viral load measured by ddPCR. c, Same experiment as in Fig. 6a , but cells were treated with increasing concentrations of Cyclosporin A (CsA). d, Similar experiment that in Fig. 5b or Fig. 5c , but combining increasing concentrations of PERKi (GSK2656157 / PERK inhibitor II) and Cyclosporin A (CsA). Data represent mean ± SD of n=6 independent experiments. e, J-Lat cell line A58 was treated with increasing concentrations of Thapsigargin (0.01, 0.1, 1 µM), Tunicamycin (0.1, 0.5, 1 µg/mL), Brefeldin A (0.01, 0.1, 1 µg/mL) and Fenretinide (0.5, 2, 5